fluticasone-propionate and Nasal-Polyps

Nasal sprays with corticosteroids deliver medication to the restricted areas including anterior and inferior parts of the nasal cavity. The fluticasone exhalation delivery system (EDS-FLU) has recently been proved to improve care by increasing superior/posterior intranasal corticosteroid deposition.. This study aims to evaluate the efficacy of EDS-FLU in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).. A systematic literature review using Pubmed, Embase, Cochrane Library, and Web of Science was conducted to identify studies assessing the effect of EDS-FLU on outcomes in patients with CRSwNP.. Of the initial 108 abstracts reviewed, 4 full-text articles were included. The 22-item sinonasal outcome test scores were significantly decreased in patients with CRSwNP after receiving EDS-FLU twice a day (93, 186, or 372 μg) for 16 weeks when compared with exhalation delivery system (EDS)-placebo (all. This is the first systematic review of the clinical outcomes in patients with CRSwNP treated with EDS-FLU. EDS-FLU produced significant improvements regarding the quality of life, smell, and endoscopic assessment of polyp grade.

Topics: Chronic Disease; Exhalation; Fluticasone; Humans; Nasal Polyps; Quality of Life; Rhinitis

Topics: Adrenal Cortex Hormones; Cataract; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Exhalation; Fluticasone; Humans; Nasal Polyps; Sinusitis

Topics: Chronic Disease; Fluticasone; Humans; Nasal Polyps; Rhinitis; Sinusitis

Topics: Fluticasone; Humans; Nasal Polyps; Sinusitis